Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082308 | 0.96 | KMT2A (0.35) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL2082309 | 0.96 | KMT2A (0.35) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL8570166 | 0.96 | KMT2A (0.35) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL2082224 | 0.90 | PSEN1 (0.36) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL2082222 | 0.90 | PSEN1 (0.36) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL25370190 | 0.88 | PSEN1 (0.34) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL4671635 | 0.84 | KMT2A (0.38) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL5238941 | 0.83 | MEN1 (0.35) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL5231750 | 0.83 | MEN1 (0.32) | BTKKMT2AGAAMEN1MAPK1 | |
| Oxalic Acid SCHEMBL483428 | 0.79 | SLC6A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1693364-B1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | DAIICHI SANKYO CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-7994344-B2 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090240066-A1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-7569599-B2 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070117988-A1 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1693364-A1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117988-A1 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | RAP1A, RHOA, MGMT | BTK 2941/4885KMT2A 1498/4885GAA 2746/4885 |
| US-20090240066-A1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | RAP1A, RHOA, MGMT | BTK 2941/4885KMT2A 1498/4885GAA 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.